Anson Funds Management’s Bluejay Diagnostics BJDX Stock Holding History

Anson Funds Management’s Portfolio BJDX Stock Details BJDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,596	Closed	-$40.5K	–	160
2024 Q3	$40.5K	Buy	1,596 +1,248	+359%	+$89.4K	﹤0.01%	151
2024 Q2	$48.6K	Buy	+348	New	+$292K	0.01%	150

Other funds holding BJDX

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Anson Funds Management's BJDX Position: Q4 2024 in Review

Anson Funds Management sold out of Bluejay Diagnostics (BJDX) in Q4 2024, closing a stake of 1,596 shares — an estimated $40.5K sold.

Anson Funds Management first reported a position in BJDX in Q2 2024 and held it in 2 quarters. The position peaked at $48.6K in Q2 2024. 3 funds tracked by Wall St. Rank hold BJDX as of Q4 2024.

Anson Funds Management reported no remaining Bluejay Diagnostics position as of Q4 2024 after selling out during the quarter.
Anson Funds Management sold 1,596 Bluejay Diagnostics shares in Q4 2024, an estimated $40.5K.
Anson Funds Management first reported a position in Bluejay Diagnostics in Q2 2024 and held it in 2 quarters.
Anson Funds Management's Bluejay Diagnostics position peaked at $48.6K in Q2 2024.
3 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q4 2024.

Based on Anson Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.